NASDAQ
PPBT

Purple Biotech

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Purple Biotech Stock Price

Vitals

Today's Low:
$1.15
Today's High:
$1.2
Open Price:
$1.18
52W Low:
$1.02
52W High:
$2.37
Prev. Close:
$1.2
Volume:
18053

Company Statistics

Market Cap.:
$26.05 million
Book Value:
2.03
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-120000
Profit Margin:
0%
Return on Assets TTM:
-24.84%
Return on Equity TTM:
-42.59%

Company Profile

Purple Biotech had its IPO on 2015-11-20 under the ticker symbol PPBT.

The company operates in the Healthcare sector and Biotechnology industry. Purple Biotech has a staff strength of 20 employees.

Stock update

Shares of Purple Biotech opened at $1.18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.15 - $1.2, and closed at $1.18.

This is a -1.67% slip from the previous day's closing price.

A total volume of 18,053 shares were traded at the close of the day’s session.

In the last one week, shares of Purple Biotech have slipped by -9.23%.

Purple Biotech's Key Ratios

Purple Biotech has a market cap of $26.05 million, indicating a price to book ratio of 0.5682 and a price to sales ratio of 58.0756.

In the last 12-months Purple Biotech’s revenue was $0 with a gross profit of $-120000 and an EBITDA of $-21760000. The EBITDA ratio measures Purple Biotech's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Purple Biotech’s operating margin was 0% while its return on assets stood at -24.84% with a return of equity of -42.59%.

In Q2, Purple Biotech’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Purple Biotech’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.11 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Purple Biotech’s profitability.

Purple Biotech stock is trading at a EV to sales ratio of 33.0832 and a EV to EBITDA ratio of -0.072. Its price to sales ratio in the trailing 12-months stood at 58.0756.

Purple Biotech stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$48.00 million
Total Liabilities
$4.88 million
Operating Cash Flow
$0
Capital Expenditure
$1000
Dividend Payout Ratio
0%

Purple Biotech ended 2024 with $48.00 million in total assets and $0 in total liabilities. Its intangible assets were valued at $48.00 million while shareholder equity stood at $42.61 million.

Purple Biotech ended 2024 with $0 in deferred long-term liabilities, $4.88 million in other current liabilities, in common stock, $-127589000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $17.20 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Purple Biotech’s total current assets stands at $19.38 million while long-term investments were $0 and short-term investments were $1.20 million. Its net receivables were $0 compared to accounts payable of $1.57 million and inventory worth $0.

In 2024, Purple Biotech's operating cash flow was $0 while its capital expenditure stood at $1000.

Comparatively, Purple Biotech paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.18
52-Week High
$2.37
52-Week Low
$1.02
Analyst Target Price
$8.67

Purple Biotech stock is currently trading at $1.18 per share. It touched a 52-week high of $2.37 and a 52-week low of $2.37. Analysts tracking the stock have a 12-month average target price of $8.67.

Its 50-day moving average was $1.21 and 200-day moving average was $1.66 The short ratio stood at 8.96 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 60.6% are held by institutions.

Frequently Asked Questions About Purple Biotech

The stock symbol (also called stock or share ticker) of Purple Biotech is PPBT

The IPO of Purple Biotech took place on 2015-11-20

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
OMAXE LTD. (OMAXE)
$43.27
-2.53
-5.52%
Genprex Inc (GNPX)
$0.55
0.03
+6.78%
$32.3
0.18
+0.56%
$0.4
0.01
+2.18%
$20.13
-0.1
-0.49%
$6.39
0.12
+1.91%
SoftBank Corp (SFBQF)
$11.53
-0.28
-2.34%
$10.4
-0.5
-4.59%
Stride Inc (LRN)
$44.16
-0.12
-0.27%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Address

4 Oppenheimer Street, Rehovot, Israel, 7670104